{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T12:56:28Z","timestamp":1789563388606,"version":"build-2803163510"},"reference-count":20,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","hpbonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["HPB"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.hpb.2019.07.002","type":"journal-article","created":{"date-parts":[[2019,8,22]],"date-time":"2019-08-22T08:24:06Z","timestamp":1566462246000},"page":"169-175","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Disease-free interval and tumor functional status can be used to select patients for resection\/ablation of liver metastases from adrenocortical carcinoma: insights from a multi-institutional study"],"prefix":"10.1016","volume":"22","author":[{"given":"Reed I.","family":"Ayabe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raja R.","family":"Narayan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha M.","family":"Ruff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael M.","family":"Wach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winifred","family":"Lo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter M.H.","family":"Nierop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth M.","family":"Steinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Taylor","family":"Ripley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy L.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bas G.","family":"Koerkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael I.","family":"D'Angelica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. Peter","family":"Kingham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William R.","family":"Jarnagin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan M.","family":"Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.hpb.2019.07.002_bib1","doi-asserted-by":"crossref","first-page":"3566","DOI":"10.1210\/jc.2018-00918","article-title":"Predictors of survival in adrenocortical carcinoma: an analysis from the national cancer database (NCDB)","volume":"103","author":"Tella","year":"2018","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.hpb.2019.07.002_bib2","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1245\/s10434-012-2358-7","article-title":"Resection of adrenocortical carcinoma liver metastasis: is it justified?","volume":"19","author":"Gaujoux","year":"2012","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.hpb.2019.07.002_bib3","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1002\/cncr.23886","article-title":"Adrenocortical carcinoma in the United States: treatment utilization and prognostic factors","volume":"113","author":"Bilimoria","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.hpb.2019.07.002_bib4","doi-asserted-by":"crossref","first-page":"2650","DOI":"10.1210\/jc.2005-2730","article-title":"Clinical and biological features in the prognosis of adrenocortical cancer: poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients","volume":"91","author":"Abiven","year":"2006","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.hpb.2019.07.002_bib5","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1056\/NEJMoa063360","article-title":"Adjuvant mitotane treatment for adrenocortical carcinoma","volume":"356","author":"Terzolo","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hpb.2019.07.002_bib6","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMoa1200966","article-title":"Combination chemotherapy in advanced adrenocortical carcinoma","volume":"366","author":"Fassnacht","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hpb.2019.07.002_bib7","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/nrendo.2013.263","article-title":"Adrenal cancer in 2013: time to individualize treatment for adrenocortical cancer?","volume":"10","author":"Stratakis","year":"2014","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.hpb.2019.07.002_bib8","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/S1470-2045(15)70081-1","article-title":"Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study","volume":"16","author":"Fassnacht","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.hpb.2019.07.002_bib9","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1002\/jso.23015","article-title":"Operative management for recurrent and metastatic adrenocortical carcinoma","volume":"105","author":"Datrice","year":"2012","journal-title":"J\u00a0Surg Oncol"},{"key":"10.1016\/j.hpb.2019.07.002_bib10","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1002\/jso.24439","article-title":"Actual 10-year survivors following resection of adrenocortical carcinoma","volume":"114","author":"Tran","year":"2016","journal-title":"J\u00a0Surg Oncol"},{"key":"10.1016\/j.hpb.2019.07.002_bib11","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1002\/cncr.11084","article-title":"Radiofrequency ablation of adrenal tumors and adrenocortical carcinoma metastases","volume":"97","author":"Wood","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.hpb.2019.07.002_bib12","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1080\/13651820500471848","article-title":"Liver resection for hepatic metastases from adrenocortical carcinoma","volume":"8","author":"Di Carlo","year":"2006","journal-title":"HPB"},{"key":"10.1016\/j.hpb.2019.07.002_bib13","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1245\/s10434-011-1564-z","article-title":"Liver resection and ablation for metastatic adrenocortical carcinoma","volume":"18","author":"Ripley","year":"2011","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.hpb.2019.07.002_bib14","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1186\/s12885-017-3506-z","article-title":"Outcome after resection of Adrenocortical Carcinoma liver metastases: a retrospective study","volume":"17","author":"Baur","year":"2017","journal-title":"BMC Cancer"},{"key":"10.1016\/j.hpb.2019.07.002_bib15","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/bjs.10414","article-title":"European Society of Endocrine Surgeons (ESES) and European Network for the Study of Adrenal Tumours (ENSAT) recommendations for the surgical management of adrenocortical carcinoma","volume":"104","author":"Gaujoux","year":"2017","journal-title":"Br J Surg"},{"key":"10.1016\/j.hpb.2019.07.002_bib16","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-18-0608","article-title":"European Society of Endocrinology Clinical Practice Guidelines on the Management of Adrenocortical Carcinoma in Adults, in collaboration with the European Network for the Study of Adrenal Tumors","volume":"179","author":"Fassnacht","year":"2018","journal-title":"Eur J Endocrinol"},{"issue":"Suppl.\u00a07","key":"10.1016\/j.hpb.2019.07.002_bib17","doi-asserted-by":"crossref","first-page":"vii131","DOI":"10.1093\/annonc\/mds231","article-title":"Adrenal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"23","author":"Berruti","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.hpb.2019.07.002_bib18","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJM199004263221705","article-title":"Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy","volume":"322","author":"Luton","year":"1990","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hpb.2019.07.002_bib19","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/bjc.1994.183","article-title":"Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients","volume":"69","author":"Haak","year":"1994","journal-title":"Br J Cancer"},{"key":"10.1016\/j.hpb.2019.07.002_bib20","doi-asserted-by":"crossref","first-page":"4619","DOI":"10.1200\/JCO.2008.17.2775","article-title":"Management of endocrine manifestations and the use of mitotane as a chemotherapeutic agent for adrenocortical carcinoma","volume":"27","author":"Veytsman","year":"2009","journal-title":"J\u00a0Clin Oncol"}],"container-title":["HPB"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1365182X19306161?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1365182X19306161?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:26:04Z","timestamp":1761265564000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1365182X19306161"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S1365182X19306161"],"URL":"https:\/\/doi.org\/10.1016\/j.hpb.2019.07.002","relation":{},"ISSN":["1365-182X"],"issn-type":[{"value":"1365-182X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Disease-free interval and tumor functional status can be used to select patients for resection\/ablation of liver metastases from adrenocortical carcinoma: insights from a multi-institutional study","name":"articletitle","label":"Article Title"},{"value":"HPB","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hpb.2019.07.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd on behalf of International Hepato-Pancreato-Biliary Association Inc.","name":"copyright","label":"Copyright"}]}}